AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00759720 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glyburide
Description: TAK-559 placebo-matching tablets, orally, once daily and glyburide stable dose, orally, once daily for up to 26 weeks.
Study NCT00411099 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT01526642 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non Invasive Ventilation
Description: NIV during night
Study NCT01165658 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Therapy
Description: The regimen of 45 Gy in 15 fractions will be delivered as a baseline, and then the fraction size will be escalated in two different intervals of 0.5 Gy each, with the ultimate dose being 60 Gy in 4 Gy fractions.
Study NCT01251354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BN83495
Description: 1 tablet of 40 mg, oral, daily until progression or death or unacceptable toxicity develops
Study NCT00115349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone (L1)
Description: The dose of L1, 75mg/kg in three divided oral doses, is the maximum dose at which toxicity has been tested in prospective trials
Study NCT00894166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Patches
Description: 21mg (1 patch) or 42mg (2 patches)nicotine patches for first five weeks (# of daily patches based on baseline carbon monoxide level); 21mg nicotine patch for 4 weeks; 14mg nicotine patch for 2 weeks and 7mg nicotine patch for 2 weeks.
Study NCT00894166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patches, then bupropion & nicotine patches (Pre-Quit)
Description: 21mg (1 patch) or 42mg (2 patches) nicotine patches for first week (# of daily patches based on baseline carbon monoxide level); starting with week 2: 150mg of bupropion once daily and 21mg (1 patch) or 42mg (2 patches)nicotine patches for first 3 days (# of daily patches based on baseline carbon monoxide level); 150mg of bupropion twice daily and 21mg (1 patch) or 42mg (2 patches)nicotine patches for 3 weeks and 4 days (# of daily patches based on baseline carbon monoxide level); 150mg of bupropion twice daily and 21mg nicotine patch for 4 weeks; 150mg of bupropion twice daily and 14mg nicotine patch for 2 weeks and 150mg of bupropion twice daily and 7mg nicotine patch for 2 weeks.
Study NCT00894166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patches, then varenicline (Pre-Quit)
Description: 21mg (1 patch) or 42mg (2 patches) nicotine patches for first week (# of daily patches based on baseline carbon monoxide level); starting with week 2: 0.5mg of varenicline once daily for first 3 days; 0.5mg of varenicline twice daily for the next 4 days; and 1mg of varenicline twice daily for the remainder of the study (11 weeks)
Study NCT00894166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patches, then nicotine patches (Pre-Quit)
Description: 21mg (1 patch) or 42mg (2 patches)nicotine patches for first five weeks (# of daily patches based on baseline carbon monoxide level); 21mg nicotine patch for 4 weeks; 14mg nicotine patch for 2 weeks and 7mg nicotine patch for 2 weeks.
Study NCT00894166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patches, then bupropion & nicotine patches (Post-Quit)
Description: 21mg (1 patch) or 42mg (2 patches) nicotine patches for first three weeks (# of daily patches based on baseline carbon monoxide level); starting with week 4: 150mg of bupropion once daily and 21mg (1 patch) or 42mg (2 patches) nicotine patches for first 3 days (# of daily patches based on baseline carbon monoxide level); 150mg of bupropion twice daily and 21mg (1 patch) or 42mg (2 patches) nicotine patches for 3 weeks and 4 days (# of daily patches based on baseline carbon monoxide level); 150mg of bupropion twice daily and 21mg nicotine patch for 4 weeks; 150mg of bupropion twice daily and 14mg nicotine patch for 2 weeks and 150mg of bupropion twice daily and 7mg nicotine patch for 2 weeks.
Study NCT00894166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patches, then varenicline (Post-Quit)
Description: 21mg (1 patch) or 42mg (2 patches) nicotine patches for first three weeks (# of daily patches based on baseline carbon monoxide level); starting with week 4: 0.5mg of varenicline once daily for first 3 days; 0.5mg of varenicline twice daily for the next 4 days; and 1mg of varenicline twice daily for the remainder of the study (11 weeks)
Study NCT00894166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patches, then nicotine patches (Post-Quit)
Description: 21mg (1 patch) or 42mg (2 patches) nicotine patches for first seven weeks (# of daily patches based on baseline carbon monoxide level); 21mg nicotine patch for 4 weeks; 14mg nicotine patch for 2 weeks and 7mg nicotine patch for 2 weeks.
Study NCT01948804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnrH Antagonist/letrozole protocol (Cetrotide; serono + Femara; Novartis Pharma AG)
Study NCT01948804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: microdose flare-up protocol (Lucrin; Abbott + Gonal F, Serono)
Study NCT01948804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antagonist/clomiphene protocol (Cetrotide; serono + Klomen, Kocak pharma)
Study NCT01948804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH antagonist protocol (Cetrotide, Serono)
Study NCT02623634 — intervention group
Intervention type: BEHAVIORAL
Intervention: Position, waveform
Description: different positions and waveform
Study NCT04553913 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cooling device
Description: device placed on patient in recovery on non surgical side to determine resolution of spinal anesthetics.
Study NCT01461941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6005
Description: 0.0% E6005 ointment applied twice daily for 4 weeks (vehicle-controlled phase), and then, following 8-week is extension phase which all subjects receive 0.2% E6005 ointment twice daily. Subjects are randomized to either 0.2% E6005 ointment group or vehicle group at a ratio of 2:1.
Study NCT01461941 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: E6005 ointment (vehicle)
Description: 0.2% E6005 ointment applied twice daily for 4 weeks (vehicle-controlled phase), and then, following 8-week is extension phase which all subjects receive 0.2% E6005 ointment twice daily. Subjects are randomized to either 0.2% E6005 ointment group or vehicle group at a ratio of 2:1.
Study NCT04332640 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VERITAS Vision System
Description: The investigators or designees will perform routine small-incision cataract surgery via phacoemulsification and use the VERITAS Vision system. The Investigator or designee will then complete a questionnaire regarding the clinical use of the VERITAS Vision system. The system log files automatically generated by the VERITAS Vision system after completion of each surgery will be collected.
Study NCT01297322 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual compression
Description: Standard of Care
Study NCT01297322 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiva VASCADE™ Vascular Closure System
Description: Investigational Hemostatic Vascular Closure System
Study NCT04929340 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotic bacteria
Description: The children are randomly allocated to a test or a control group with aid of computer-generated numbers at the time of consent. After the treatment, children in the test group are given 5 drops per day containing probiotic bacteria (Lactobacillus reuteri Protectis DSM 17938, Biogaia AB, Sweden) before bedtime. One dose consists of a minimum of 100 million live bacteria. Children in control group are given 5 drops per day (containing no bacteria).
Study NCT04929340 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Children in control group are given 5 drops per day (containing no bacteria).
Study NCT02180503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356 BS PIB - low dose
Study NCT00652756 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of ventilator during patient transport (Versamed iVent)
Description: The goal of the transport ventilator is to provide optimal ventilation.
Study NCT00652756 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Bag-valve ventilation
Description: Use of bag-valve ventilation during patient transport.
Study NCT05861388 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: implant placement
Description: 2 implants were placed at position of lower 2nd premolar and 2nd molar
Study NCT05861388 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: implant placement
Description: 2 implants were placed at position of lower 2nd premolar and 2nd molar
Study NCT04210765 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene Citrate
Description: Clomiphene citrate used in incremental doses in nonresponsive cases.
Study NCT02023125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: A single 600-mg oral dose of alectinib will be administered in a fasted or fed condition.
Study NCT02023125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Esomeprazole 40 mg will be administered orally once daily for 6 days prior to alectinib administration.
Study NCT02023125 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Fat and Calorie Meal
Description: High fat and calorie meal served prior to alectinib administration
Study NCT02023125 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Meal
Description: Standard meal served prior to alectinib administration
Study NCT02180503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356 BS tablet - low dose
Study NCT02180503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356 BS PIB - high dose
Study NCT01828320 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy for Insomnia, Interpersonal and Social Rhythms Therapy, Chronotherapy
Study NCT01828320 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Study NCT03772379 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tooth borne hyrax expander
Description: ready made four stainless steel bands will be supported on the first premolars and first permanent molars and to which the palatal expander will be soldered to form the Hyrax,.The appliance will be activated one quarter turn per day untill reaching maximum amount of lateral expansion of the jack screw. the patients will be recalled twice per week to evaluate the progress of treatment.
Study NCT03772379 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: microosteoperforation
Description: ready made four stainless steel bands supported on the first premolars and first permanent molars and to which the palatal expander will be soldered to form the Hyrax.No activation will be provided to the hyrax expander before the micro-osteoperforation is performed.~Microosteoperforation will applied bilaterally on the buccal surface between the roots of teeth at the level of mucoginival junction, starting from the distal of canine till the distal of the first permanent molar using a small sized surgical bur mounted on a hand piece .
Study NCT06755580 — intervention group
Intervention type: PROCEDURE
Intervention: spinopelvic fixation
Description: open and minimally invasive spinopelvic fixation for unstable or dislocated high-energy sacral fractures
Study NCT04487236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-A-1041 50mg BID
Description: Orally 21days for one cycle
Study NCT04487236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-A-1041 100mg BID
Description: Orally 21days for one cycle
Study NCT04487236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-A-1041 200mg BID
Description: Orally 21days for one cycle
Study NCT04487236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-A-1041 400mg BID
Description: Orally 21days for one cycle
Study NCT04487236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-A-1041 600mg BID
Description: Orally 21days for one cycle
Study NCT04487236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-A-1041 800mg BID
Description: Orally 21days for one cycle
Study NCT04487236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-A-1041 1000mg BID
Description: Orally 21days for one cycle
Study NCT04487236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-A-1041 Level 1 +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle
Description: ZN-A-1041 level 1 BID; Capecitabine 1000 mg/m2 BID Trastuzumab 8 mg/kg iv. First Cycle
Study NCT04487236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-A-1041 Level 2 +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle
Description: ZN-A-1041 level 2 BID; Capecitabine 1000 mg/m2 BID Trastuzumab 8 mg/kg iv. First Cycle
Study NCT04487236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-A-1041 MAD +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle
Description: ZN-A-1041 MAD BID; Capecitabine 1000 mg/m2 BID Trastuzumab 8 mg/kg iv. First Cycle
Study NCT04487236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-A-1041+Capecitabine + Trastuzumab 8 mg/kg iv. First Cycle
Description: Base on 1b ZN-A-1041 dose Base on 1b Capecitabine dose Base on 1b Trastuzumab dose
Study NCT01121549 — intervention group
Intervention type: DRUG
Intervention: Aromasin
Description: 25 mg daily continuously
Study NCT00002527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin
Study NCT00002527 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT01063517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olaparib
Description: 100mg BID oral tablet continuous
Study NCT01063517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: iv infusion 80mg/m2 on Day 1, 8 and 15 of a 28 day cycle
Study NCT01063517 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: iv infusion 80mg/m2 on Day 1, 8 and 15 of a 28 day cycle
Study NCT01063517 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 100mg BID oral tablet to match olaparib tablet
Study NCT02328352 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BP selfstanding felt
Description: intervention of laparotomy with the incision of 10 cm navel-pubis will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, and muscles. Ten rabbits (hereafter defined as BPR1-BPR10) will receive 2x2cm2 samples of BP selfstanding felt in a pocket created between muscular fascia and large muscles of the abdominal wall.
Study NCT02180503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356 BS tablet - high dose
Study NCT02180503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356 BS tablet - high dose with food
Study NCT00437606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GK Activator (2)
Description: 100mg po
Study NCT00437606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethanol
Description: 40g po
Study NCT02328352 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PP mesh
Description: intervention of laparotomy with the incision of 10 cm navel-pubis will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, and muscles. A 2x2cm2 sample of PR (polypropylene) prosthesis was implanted without stitches into a pocket between large abdominal muscle and abdominal fascia
Study NCT02328352 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BP intraperitoneal mesh
Description: Laparotomy on the linea alba carried out deeply for entering into the abdominal cavity, a 2x2cm2 BP sample implantation with the rough side facing the parietal peritoneum surface and the smooth and brilliant surface facing to the visceral peritoneum and gut
Study NCT02328352 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: observational intervention in 5 rabbits with the same body weight and the same age will be observed and will be feeded in the same way of the BP device intraperitoneal implanted group
Study NCT04423328 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: acupressure
Description: self-acupressure
Study NCT05292625 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UC-MSC infusion via intravenous route
Description: Patients assigned to UC-MSC administration groups will receive two administrations at a dose of 1.5 million cells/kg patient body weight via the intravenous (IV) route with a 3-month intervening interval
Study NCT05292625 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UC-MSC infusion via intrathecal route
Description: Patients assigned to UC-MSC administration groups will receive two administrations at a dose of 1.5 million cells/kg patient body weight via the intrathecal route with a 3-month intervening interval
Study NCT05292625 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard stroke treatment and rehabilitation therapy
Description: Each patient can receive up to 30 days of rehabilitation therapy
Study NCT05292625 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: standard stroke treatment and rehabilitation therapy
Description: Each patient can receive up to 30 days of rehabilitation therapy
Study NCT04218617 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diagnostic MRI
Description: Diagnostic MRI
Study NCT04218617 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Diagnostic MRI
Description: Diagnostic MRI
Study NCT04218617 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Planning MRI
Description: Planning MRI: high definition (HD) MRI of the region of interest (1 vertebral level above and below the level(s) being treated)
Study NCT04218617 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Planning MRI
Description: Planning MRI: high definition (HD) MRI of the region of interest (1 vertebral level above and below the level(s) being treated)
Study NCT04218617 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulation CT
Description: Simulation CT is obtained (1.5 mm slice thickness)
Study NCT04218617 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Simulation CT
Description: Simulation CT is obtained (1.5 mm slice thickness)
Study NCT04218617 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: QOL assessment
Description: QOL assessment
Study NCT04218617 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: QOL assessment
Description: QOL assessment
Study NCT04218617 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brief pain inventory (BPI)
Description: Brief pain inventory (BPI), including narcotic assessment
Study NCT04218617 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brief pain inventory (BPI)
Description: Brief pain inventory (BPI), including narcotic assessment
Study NCT04218617 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: sSRS in 1 fraction
Description: sSRS 18 Gy in 1 fraction
Study NCT04218617 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: sSRS in 2 fraction
Description: sSRS 24 Gy in 2 fractions to be delivered either on consecutive days or one day apart.
Study NCT02292511 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Square-stepping exercise
Description: In a group setting, an instructor will demonstrate walking patterns on a gridded mat to the participants and the participants must memorize and repeat the patterns on their own. This program has over 200 patterns that increase in difficulty from beginner to advanced. Eighty percent of the group must successfully complete the patterns to move onto the next pattern. Social engagement is encouraged.
Study NCT01856387 — intervention group
Intervention type: BIOLOGICAL
Intervention: high neutrophil to lymphocyte ratio
Study NCT01856387 — intervention group
Intervention type: OTHER
Intervention: normal neutrophil-to Lymphocyte ratio
Study NCT01270620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: comparison of the incidence in delirium and post-operative cognitive dysfunction from propofol and desflurane in patients under general anesthesia
Study NCT01270620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Description: comparison of the incidence in delirium and post-operative cognitive dysfunction from propofol and desflurane in patients under general anesthesia
Study NCT04625192 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trephine osteotomy
Description: * Using a trephine on a straight implant handpiece (at approximately 1800 rpm) with copious irrigation to avoid overheating the bone, a round bone cut will be made 4 -5 mm above the crest of the alveolar ridge.~* The trephine is positioned perpendicular to the lateral wall, removing the outer cortex with a very gentle touch to avoid tearing the schneiderian membrane.
Study NCT01757899 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone Arm
Description: Day 0 - Loading dose 1 mg/kg IV bolus mixed in 5 mL NS (30 min) followed by continuous infusion Days 0 to 07 - 1 mg/kg/day mixed in 24cc NS and infused at 1 cc/hr Days 08 to 10 - 0.5 mg/kg/day mixed in 24cc NS and infused at 1 cc/hr Days 11 to 12 - 0.25 mg/kg/day Days 13 to 14 - 0.125 mg/kg/day